EUVIMEDEUVIMED entdecken
Open Access

Antibodies targeting the fusion peptide on the HIV envelope provide protection to rhesus macaques against mucosal SHIV challenge

Amarendra Pegu iD, Sarah E Lovelace iD, Megan E DeMouth iD, Michelle D Cully iD, Daniel J Morris iD, Yingying Li iD, Keyun Wang iD, Stephen D Schmidt iD, Misook Choe iD, Cuiping Liu, Xuejun Chen iD, Elise Viox iD und 14 weitere

Science Translational Medicine · 2024

DOI: 10.1126/scitranslmed.adh9039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2024. Verfasst von Amarendra Pegu und 25 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Simian Acquired Immunodeficiency Syndrome, HIV Infections, Simian Immunodeficiency Virus, HIV-1. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The fusion peptide (FP) on the HIV-1 envelope (Env) trimer can be targeted by broadly neutralizing antibodies (bNAbs). Here, we evaluated the ability of a human FP-directed bNAb, VRC34.01, along with two vaccine-elicited anti-FP rhesus macaque mAbs, DFPH-a.15 and DF1W-a.01, to protect against simian-HIV (SHIV) BG505 challenge. VRC34.01 neutralized SHIV BG505 with a 50% inhibitory concentration (IC 50 ) of 0.58 μg/ml, whereas DF1W-a.01 and DFPH-a.15 were 4- or 30-fold less potent, respectively. VRC34.01 was infused into four rhesus macaques at a dose of 10 mg/kg and four rhesus macaques at a dose of 2.5 mg/kg. The animals were intrarectally challenged 5 days later with SHIV BG505 . In comparison with all 12 control animals that became infected, all four animals infused with VRC34.01 (10 mg/kg) and three out of four animals infused with VRC34.01 (2.5 mg/kg) remained uninfected. Because of the lower potency of DF1W-a.01 and DFPH-a.15 against SHIV BG505 , we infused both Abs at a higher dose of 100 mg/kg into four rhesus macaques each, followed by SHIV BG505 challenge 5 days later. Three of four animals that received DF1W-a.01 were protected against infection, whereas all animals that received DFPH-a.15 were protected. Overall, the protective serum neutralization titers observed in these animals were similar to what has been observed for other bNAbs in similar SHIV infection models and in human clinical trials. In conclusion, FP-directed mAbs can thus provide dose-dependent in vivo protection against mucosal SHIV challenges, supporting the development of prophylactic vaccines targeting the HIV-1 Env FP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Simian Acquired Immunodeficiency SyndromeHIV InfectionsSimian Immunodeficiency VirusHIV-1AIDS VaccinesAnimalsHumansMacaca mulattaBroadly Neutralizing AntibodiesHIV AntibodiesAntibodies, MonoclonalPeptidesAntibodies, Neutralizing

Substanzen

Broadly Neutralizing AntibodiesHIV AntibodiesAntibodies, MonoclonalPeptidesAntibodies, NeutralizingAIDS Vaccines

Autor:innen und Institutionen

  • Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
  • Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

ORCID-Profile: Amarendra Pegu, Sarah E Lovelace, Megan E DeMouth, Michelle D Cully, Daniel J Morris, Yingying Li, Keyun Wang, Stephen D Schmidt, Misook Choe, Xuejun Chen, Elise Viox, Ariana Rowshan, Baoshan Zhang, Kai Xu, Hongying Duan, Li Ou, John-Paul Todd, Rui Kong, Hui Li, George M Shaw, Nicole A Doria-Rose, Peter D Kwong, Richard A Koup

Förderung

  • NIAID NIH HHS
  • Intramural NIH HHS

Zitieren

APA

Pegu, A., Lovelace, S. E., DeMouth, M. E., Cully, M. D., Morris, D. J., Li, Y., Wang, K., Schmidt, S. D., Choe, M., Liu, C., Chen, X., Viox, E., Rowshan, A., Taft, J. D., Zhang, B., Xu, K., Duan, H., Ou, L., Todd, J. P., …, & Mascola, J. R. (2024). Antibodies targeting the fusion peptide on the HIV envelope provide protection to rhesus macaques against mucosal SHIV challenge. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adh9039

Vancouver

Pegu A, Lovelace SE, DeMouth ME, Cully MD, Morris DJ, Li Y, et al. Antibodies targeting the fusion peptide on the HIV envelope provide protection to rhesus macaques against mucosal SHIV challenge. Science Translational Medicine. 2024. doi:10.1126/scitranslmed.adh9039

BibTeX
@article{Pegu2024,
  author = {Pegu, Amarendra and Lovelace, Sarah E and DeMouth, Megan E and Cully, Michelle D and Morris, Daniel J and Li, Yingying and Wang, Keyun and Schmidt, Stephen D and Choe, Misook and Liu, Cuiping and Chen, Xuejun and Viox, Elise and Rowshan, Ariana and Taft, Justin D and Zhang, Baoshan and Xu, Kai and Duan, Hongying and Ou, Li and Todd, John-Paul and Kong, Rui and Li, Hui and Shaw, George M and Doria-Rose, Nicole A and Kwong, Peter D and Koup, Richard A and Mascola, John R},
  title = {Antibodies targeting the fusion peptide on the HIV envelope provide protection to rhesus macaques against mucosal SHIV challenge},
  journal = {Science Translational Medicine},
  year = {2024},
  doi = {10.1126/scitranslmed.adh9039}
}
Kostenlos starten →